肝动脉化疗栓塞术联合或不联合全身治疗？ - Suppr

Suppr

超能文献

TACE with or without systemic therapy?

作者信息

Dufour Jean-François

出版信息

J Hepatol. 2012 Jun;56(6):1224-5. doi: 10.1016/j.jhep.2012.02.011. Epub 2012 Mar 5.

DOI:10.1016/j.jhep.2012.02.011

PMID:22402292

Abstract

摘要

相似文献

TACE with or without systemic therapy?

J Hepatol. 2012 Jun;56(6):1224-5. doi: 10.1016/j.jhep.2012.02.011. Epub 2012 Mar 5.

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335.

Major achievements in hepatocellular carcinoma.

Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0.

Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?

J Gastroenterol Hepatol. 2011 Nov;26(11):1585-6. doi: 10.1111/j.1440-1746.2011.06901.x.

Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.

Dig Liver Dis. 2012 May;44(5):361-2. doi: 10.1016/j.dld.2012.02.014. Epub 2012 Mar 14.

Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization.

J Hepatol. 2013 Jan;58(1):194. doi: 10.1016/j.jhep.2012.08.028. Epub 2012 Oct 6.

Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.

Asia Pac J Clin Oncol. 2012 Jun;8(2):111-4. doi: 10.1111/j.1743-7563.2012.01551.x.

Reply to: "Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization".

J Hepatol. 2013 Jan;58(1):195. doi: 10.1016/j.jhep.2012.09.033. Epub 2012 Oct 6.

[Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):716-8.

Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.

J Gastroenterol. 2012 Mar;47(3):343-6. doi: 10.1007/s00535-011-0511-x. Epub 2011 Dec 21.

引用本文的文献

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.

Drug Des Devel Ther. 2022 Sep 30;16:3421-3429. doi: 10.2147/DDDT.S372276. eCollection 2022.

Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.

Cardiovasc Intervent Radiol. 2021 Sep;44(9):1394-1402. doi: 10.1007/s00270-021-02846-w. Epub 2021 May 4.

Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.

Liver Cancer. 2020 Jun;9(3):308-325. doi: 10.1159/000505692. Epub 2020 Feb 19.

Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma.

BMC Cancer. 2019 Apr 30;19(1):409. doi: 10.1186/s12885-019-5570-z.

Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review.

J Hepatocell Carcinoma. 2017 Jul 27;4:105-110. doi: 10.2147/JHC.S103661. eCollection 2017.

Current systemic treatment of hepatocellular carcinoma: A review of the literature.

World J Hepatol. 2015 Jun 8;7(10):1412-20. doi: 10.4254/wjh.v7.i10.1412.

CKAP4 inhibited growth and metastasis of hepatocellular carcinoma through regulating EGFR signaling.

Tumour Biol. 2014 Aug;35(8):7999-8005. doi: 10.1007/s13277-014-2000-3. Epub 2014 May 18.

Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.

Liver Cancer. 2012 Nov;1(3-4):201-15. doi: 10.1159/000343835.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验